Pds biotech to participate at the h.c. wainwright 25th annual global investment conference

Princeton, n.j., sept. 06, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (pds biotech or the company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the company's proprietary t cell activating platforms, today announced that dr. frank bedu-addo, chief executive officer of pds biotech, will participate and present an overview of the company and its programs at the h.c. wainwright 25th annual global investment conference.
PDSB Ratings Summary
PDSB Quant Ranking